The first non-invasive bladder cancer detection test that integrates life science, physics, and data science.
CANCER CELLS DETECTION
A non-invasive bladder cancer detection test
Cellens uses a proprietary AFM imaging method to precisely show that the cell surfaces could be used to uncover the difference in cells of patients with active cancer vs. non-active cancer
We differentiate the
CANCER CELLS | NORMAL CELLS
This is a CELL
We check the cell’s ADHESION & SOFTNESS
Cancer cells are less ADHESIVE & SOFT
Normal Cells are ADHESIVE & SOFT
The cell surface is not flat and covered with long flexible molecules, such as glycocalyx, which alters at cancer progression and immune system regulation. Our cell scanning assay uses nanoscale imaging and machine learning techniques to detect those changes and provide a quantitative diagnostic score for urologists at an accuracy of 94%.
LET'S RE-THINK CANCER DIAGNOSTIC TESTS AND THEIR COSTS
Cellens aims to reduce unnecessary invasive
procedures of cystoscopy and provides a resource-efficient monitoring pathway
for urologists and healthcare providers. Our technology takes approximately 30 minutes to process a patient sample with minimal human involvement, significantly cutting costs per test while increasing reliability.
VOIDED URINE FIXATION
ATOMIC FORCE MICROSCOPE IMAGES 5~10 CELLS (30 MINS)
TRAINED MACHINE LEARNING ANALYSIS
Bladder cancer monitoring doesn’t always have to be painful or costly. Medical practitioners can reliably monitor patients with bladder cancer history for recurrence with Cellens’ solution and reduce the frequency of invasive and expensive cystoscopy visits. Cellens provides painless, timely care and relief for bladder cancer patients whose risks of having cystoscopy might outweigh its benefits.
Solution that is assessed in exam rooms
SO, WHY CELLENS?
A solution that extends beyond bladder cancer monitoring.
Our evaluations with patients have shown 94% accuracy in detecting bladder cancer, and it will only get better as our algorithm improves itself after every test.
Only 30 minutes to process a test might seem great, but Cellens is determined to reduce that time even more through investments in R&D to support our patients better.
We are committed to make bladder cancer monitoring more reliable at lower costs. Our business model relies on cost reduction as we serve more patients.